Sign In
Buy ANAB
$53.36
-1.68 (-3.05%)
At Close: Jul 31, 2026
AnaptysBio: Upcoming Catalyst Seems Like Quite The Gamble
05:20pm, Tuesday, 02'nd Mar 2021
ANAB has a wholly-owned pipeline and partnered pipeline. ANAB has an upcoming catalyst in Q1'21, results from the POPLAR trial of ANB019 in palmoplantar pustulosis.
Why AnaptysBio Was a Stock Market Star on Friday
06:55pm, Friday, 26'th Feb 2021
There was some encouraging news from across the Atlantic.
Why AnaptysBio Fell by as Much as 10% Today
06:41pm, Tuesday, 23'rd Feb 2021
Perhaps no news is bad news for the ambitious biotech.
AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: Should You Buy?
01:41pm, Monday, 22'nd Feb 2021
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why AnaptysBio Trounced the Market on Thursday
07:05pm, Thursday, 11'th Feb 2021
The biotech got a sharp upward shift in recommendation and target price from a prominent analyst.
AnaptysBio: Troubled History Of Drug Development
12:59pm, Thursday, 11'th Feb 2021
AnaptysBio has a number of molecules in pipeline and in partnered programs, but it has a history of failures for one molecule. The company's cash position is good.
AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
04:15pm, Thursday, 07'th Jan 2021
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co
AnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% Upside
01:26pm, Monday, 30'th Nov 2020
AnaptysBio is a $675M clinical-stage biotechnology company focused on developing immunology therapeutics based around emerging immune control mechanisms applicable to inflammation and immuno-oncology.
AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference
09:25am, Friday, 13'th Nov 2020
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates
04:00pm, Wednesday, 04'th Nov 2020
SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)
05:28pm, Monday, 26'th Oct 2020
Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise i
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Allscripts Healthcare Solutions Shares Jump
12:00am, Wednesday, 14'th Oct 2020
Toward the end of trading Wednesday, the Dow traded down 0.45% to 28550.31 while the NASDAQ fell 0.75% to 11775.45. The S&P also fell, dropping 0.56% to 3,492.39.
The U.S....
Shuman Glenn & Stecker Investigates AnaptysBio, Inc.
12:00am, Monday, 24'th Aug 2020
Shuman, Glenn & Stecker Investigates AnaptysBio, Inc.
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates
01:25pm, Monday, 10'th Aug 2020
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -5.33% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates
12:05pm, Monday, 10'th Aug 2020
* Interim 8-Week Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Did Not Demonstrate Statistical Significance For Either Q4W or Q8W Versus Placebo; Compan
